Non‐transplantable recurrence after percutaneous thermal ablation of ≤3‐cm HCC: Predictors and implications for treatment allocation

Cecilia Gozzo, Margaux Hermida, Astrid Herrero, Fabrizio Panaro, Christophe Cassinotto, Azhar Meerun Mohamad, Eric Assenat, Chloé Guillot, Carole Allimant, Valentina Schembri, Antonio Basile, Sébastien Dharancy, José Ursic‐Bedoya, Boris Guiu – 5 August 2022 – Percutaneous thermal ablation (PTA), resection, and liver transplantation are the standard curative options for hepatocellular carcinoma (HCC). Liver transplantation yields the best long‐term outcomes but is limited by graft shortage.

Cellular communication network factor 1‐stimulated liver macrophage efferocytosis drives hepatic stellate cell activation and liver fibrosis

Ki‐Hyun Kim, Naiyuan Cheng, Lester F. Lau – 4 August 2022 – Following inflammatory injury in the liver, neutrophils quickly infiltrate the injured tissue to defend against microbes and initiate the repair process; these neutrophils are short lived and rapidly undergo apoptosis. Hepatic stellate cells (HSCs) are the principal precursor cells that transdifferentiate into myofibroblast‐like cells, which produce a large amount of extracellular matrix that promotes repair but can also lead to fibrosis if the injury becomes chronic.

Mortality after transjugular intrahepatic portosystemic shunt in older adult patients with cirrhosis: A validated prediction model

Francesco Vizzutti, Ciro Celsa, Vincenza Calvaruso, Marco Enea, Salvatore Battaglia, Laura Turco, Marco Senzolo, Silvia Nardelli, Roberto Miraglia, Davide Roccarina, Claudia Campani, Dario Saltini, Cristian Caporali, Federica Indulti, Stefano Gitto, Alberto Zanetto, Gabriele Di Maria, Marcello Bianchini, Maddalena Pecchini, Silvia Aspite, Chiara Di Bonaventura, Michele Citone, Tomas Guasconi, Fabrizio Di Benedetto, Umberto Arena, Fabrizio Fanelli, Luigi Maruzzelli, Oliviero Riggio, Patrizia Burra, Antonio Colecchia, Erica Villa, Fabio Marra, Calogero Cammà, Filippo Schepis – 2 August 2022

The NADPH oxidase NOX4 regulates redox and metabolic homeostasis preventing HCC progression

Irene Peñuelas‐Haro, Rut Espinosa‐Sotelo, Eva Crosas‐Molist, Macarena Herranz‐Itúrbide, Daniel Caballero‐Díaz, Ania Alay, Xavier Solé, Emilio Ramos, Teresa Serrano, María L. Martínez‐Chantar, Ulla G. Knaus, José M. Cuezva, Antonio Zorzano, Esther Bertran, Isabel Fabregat – 2 August 2022

Enhanced mitochondrial activity reshapes a gut microbiota profile that delays NASH progression

María Juárez‐Fernández, Naroa Goikoetxea‐Usandizaga, David Porras, María Victoria García‐Mediavilla, Miren Bravo, Marina Serrano‐Maciá, Jorge Simón, Teresa C. Delgado, Sofía Lachiondo‐Ortega, Susana Martínez‐Flórez, Óscar Lorenzo, Mercedes Rincón, Marta Varela‐Rey, Leticia Abecia, Héctor Rodríguez, Juan Anguita, Esther Nistal, María Luz Martínez‐Chantar, Sonia Sánchez‐Campos – 2 August 2022

Mouse model of NASH that replicates key features of the human disease and progresses to fibrosis stage 3

Kristy St. Rose, Jun Yan, Fangxi Xu, Jasmine Williams, Virginia Dweck, Deepak Saxena, Robert F. Schwabe, Jorge Matias Caviglia – 2 August 2022 – Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease in the United States and the world; with no Food and Drug Administration–approved pharmacological treatment available, it remains an area of unmet medical need. In nonalcoholic steatohepatitis (NASH), the most important predictor of clinical outcome is the fibrosis stage.

Subscribe to